Texas Capital Bancshares Inc TX Buys 2,014 Shares of Novo Nordisk A/S (NYSE:NVO)

Texas Capital Bancshares Inc TX lifted its stake in shares of Novo Nordisk A/S (NYSE:NVOFree Report) by 97.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,073 shares of the company’s stock after purchasing an additional 2,014 shares during the quarter. Texas Capital Bancshares Inc TX’s holdings in Novo Nordisk A/S were worth $370,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. ICW Investment Advisors LLC raised its position in shares of Novo Nordisk A/S by 0.3% during the second quarter. ICW Investment Advisors LLC now owns 21,922 shares of the company’s stock worth $3,548,000 after acquiring an additional 63 shares during the last quarter. Stone House Investment Management LLC increased its holdings in Novo Nordisk A/S by 55.3% in the second quarter. Stone House Investment Management LLC now owns 177 shares of the company’s stock worth $29,000 after purchasing an additional 63 shares in the last quarter. Chilton Capital Management LLC increased its holdings in Novo Nordisk A/S by 0.6% in the second quarter. Chilton Capital Management LLC now owns 10,063 shares of the company’s stock worth $1,628,000 after purchasing an additional 63 shares in the last quarter. Red Wave Investments LLC increased its holdings in Novo Nordisk A/S by 2.3% in the second quarter. Red Wave Investments LLC now owns 3,068 shares of the company’s stock worth $496,000 after purchasing an additional 69 shares in the last quarter. Finally, Chicago Partners Investment Group LLC grew its stake in Novo Nordisk A/S by 0.7% in the second quarter. Chicago Partners Investment Group LLC now owns 10,863 shares of the company’s stock valued at $1,720,000 after acquiring an additional 73 shares during the period. 6.41% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 0.6 %

Shares of NYSE:NVO traded down $0.69 during mid-day trading on Wednesday, hitting $121.54. 3,073,354 shares of the company traded hands, compared to its average volume of 4,914,535. The stock has a market cap of $545.41 billion, a P/E ratio of 45.18, a P/E/G ratio of 2.06 and a beta of 0.41. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. Novo Nordisk A/S has a 12-month low of $67.66 and a 12-month high of $124.86. The stock has a 50-day moving average price of $111.45 and a two-hundred day moving average price of $92.58.

Novo Nordisk A/S (NYSE:NVOGet Free Report) last announced its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The company had revenue of $9.51 billion for the quarter, compared to analysts’ expectations of $9.14 billion. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a Semi-Annual dividend, which will be paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th will be given a $0.664 dividend. The ex-dividend date is Friday, March 22nd. This represents a yield of 0.9%. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s payout ratio is currently 22.92%.

Analyst Ratings Changes

A number of brokerages have commented on NVO. TD Cowen raised their price objective on Novo Nordisk A/S from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Monday, December 4th. Cantor Fitzgerald reissued an “overweight” rating and issued a $140.00 price objective on shares of Novo Nordisk A/S in a research note on Tuesday, February 20th. UBS Group began coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating for the company. Finally, Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective for the company. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and an average target price of $121.25.

Get Our Latest Stock Analysis on NVO

About Novo Nordisk A/S

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Featured Stories

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.